December 9th, 2016
•Here we describe a protocol aimed at investigating the impact of aberrant splicing on drug resistance in solid tumors and hematological malignancies. To this goal, we analyzed the transcriptomic profiles of parental and resistant in vitro models through RNA-seq and established a qRT-PCR based method to validate candidate genes.
Tags
Related Videos
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Evaluating In Vitro DNA Damage Using Comet Assay
Establishment of Gastric Cancer Patient-derived Xenograft Models and Primary Cell Lines
In Vitro Assay to Study Tumor-macrophage Interaction
In Vitro Evaluation of Oncogenic Transformation in Human Mammary Epithelial Cells
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Optimization of Performance Parameters of the TAGGG Telomere Length Assay
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved